Geneoscopy

We are thrilled to announce that the Centers for Medicare & Medicaid Services (CMS) has approved national coverage for ColoSense®, making it accessible to approximately 65 million eligible Medicare beneficiaries. This milestone marks a major step forward, aligning CMS coverage with recent ACS and NCCN guidelines to establish ColoSense as a preferred, noninvasive screening option.
As the first FDA-approved stool-based RNA test, ColoSense directly addresses a major barrier to at-home screening by eliminating the need for patients to complete the stool scraping or complex sample manipulation. Given that more than half of all colorectal cancer diagnoses still occur in individuals aged 65 and older, providing this simplified screening method is critical for improving screening completion rates.
"Restructuring the framework to include high-sensitivity tests like ColoSense demonstrates the importance that CMS places on earlier detection through preventive screening," notes CEO Andrew Barnell.
A strategic collaboration with Labcorp will further expand access to ColoSense, enabling broader provider and patient adoption through Labcorp’s nationwide network.
🔗 Read our full press release to learn more about this landmark coverage decision: https://www.businesswire.com/news/home/20260605649071/en/CMS-Grants-Medicare-Coverage-for-ColoSense-Expanding-Access-to-Simplified-Noninvasive-Colorectal-Cancer-Screening

Stronger Together, The Geneoscopy Team Onsite

What an incredible week! We brought our entire team together at our St. Louis headquarters for an energizing onsite filled with collaboration, alignment, and shared vision. As well as some Top Golf Fun!

The energy from our expanding team was incredible, with everyone coming together and fully engaged. We are more united than ever in our mission to bring approachable, non-invasive screening options to patients and providers nationwide. There is so much momentum ahead for the rest of 2026, and we can’t wait to share what's coming next!

A Historic Milestone for Colorectal Cancer Screening

We are proud to announce that the American Cancer Society (ACS) has updated its colorectal cancer screening guidelines to include ColoSense® as a preferred stool-based testing option!

This update marks the first time a noninvasive RNA-based test has been included in ACS screening guidelines for detecting colorectal cancer and advanced adenomas in average-risk adults aged 45 or older. Widely considered a gold standard in oncology and public health, the ACS guidelines are developed by top experts who evaluate only the highest-quality evidence to assess real-world impact.

"ColoSense combines clinical accuracy with a patient-friendly experience and can help identify patients most at risk of cancer progression" notes Andrew Barnell, CEO and co-founder.

To drive broader provider and patient adoption, our strategic collaboration with Labcorp will expand access to ColoSense in the coming months, utilizing Labcorp’s extensive nationwide network to make this advanced screening option widely available.

With 41% of adults aged 45 and older still unscreened, this guideline update is a critical step forward in making accurate, at-home screening approachable and reliable.

Read the full press release here: https://www.businesswire.com/news/home/20260527486679/en

Business Wire The global leader in press release distribution and regulatory disclosure. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach.

From groundbreaking research to FDA-approved innovation, Dr. Erica Barnell is transforming the future of preventive healthcare. As co-founder and Chief Medical and Science Officer of Geneoscopy, she is helping revolutionize colorectal cancer screening and improving early detection for patients everywhere.

https://www.eventbrite.com/e/edge-of-possible-by-tedxstlouis-tickets-1979125774468?aff=oddtdtcreator

That’s a wrap on !

Our team spent last week in Chicago at the world's premier meeting for GI professionals at Digestive Disease Week. We were thrilled to present our latest research on colorectal cancer screening and IBD diagnostics, showcasing that non-invasive, RNA-based technology is changing the game for patients.

A huge thank you to everyone who stopped by our posters to discuss our findings. Our team left Chicago more motivated than ever to continue our work in expanding access to early, accurate screening.